400
Participants
Start Date
September 1, 2022
Primary Completion Date
December 31, 2024
Study Completion Date
December 31, 2025
Dexamethasone
Single drug in non-severe group; combined with etoposide±ruxolitinib in severe group.
Etoposide
Used in severe group combined with etoposide.
Ruxolitinib
Single drug in non-severe group; combined with etoposide and dexamethasone in severe group.
RECRUITING
The Children's Hospital of Zhejiang University School of Medicine, Hangzhou
The Second Hospital of Anhui Medical University
OTHER
Union hospital of Fujian Medical University
OTHER
Children's Hospital of Fudan University
OTHER
Zunyi Medical College
OTHER
Hunan Provincial People's Hospital
OTHER
Tongji Hospital
OTHER
Children's Hospital of Nanjing Medical University
OTHER
The Affiliated Hospital of Qingdao University
OTHER
Qilu Hospital of Shandong University
OTHER
Shanghai Children's Medical Center
OTHER
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
OTHER
Shanghai Children's Hospital
OTHER
Shenzhen Children's Hospital
OTHER_GOV
West China Second University Hospital
OTHER
Children's Hospital of Soochow University
OTHER
Second Affiliated Hospital of Wenzhou Medical University
OTHER
Wuhan Children's Hospital
OTHER
Institute of Hematology & Blood Diseases Hospital, China
OTHER
The Third Xiangya Hospital of Central South University
OTHER
First Affiliated Hospital, Sun Yat-Sen University
OTHER
The Children's Hospital of Zhejiang University School of Medicine
OTHER